• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 12:23:57 PM ET
    $FIXX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FIXX alert in real time by email
    SC 13G/A 1 fixx13gadec20.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Homology Medicines, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 438083107 (CUSIP NUMBER) December 31, 2020 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1. Name of Reporting Person T. ROWE PRICE ASSOCIATES, INC. 52-0556948 2. Check the Appropriate Box if a Member of a Group NOT APPLICABLE 3. SEC Use Only 4. Citizenship or Place of Organization Maryland Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power* 436,358 6. Shared Voting Power* 0 7. Sole Dispositive Power* 1,986,298 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 1,986,298 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares NOT APPLICABLE 11. Percent of Class Represented by Amount in Row 9 4.3% 12. Type of Reporting Person IA *Any shares reported in Items 5 and 6 are also reported in Item 7. Item 1(a) Name of Issuer: Homology Medicines, Inc. Item 1(b) Address of Issuer's Principal Executive Offices: ONE PATRIOTS PARK, BEDFORD, MASSACHUSETTS 01730 Item 2(a) Name of Person(s) Filing: (1) T. ROWE PRICE ASSOCIATES, INC. ("Price Associates") Item 2(b) Address of Principal Business Office: 100 E. Pratt Street, Baltimore, MD 21202 Item 2(c) Citizenship or Place of Organization: (1) Maryland Item 2(d) Title of Class of Securities: COMMON STOCK Item 2(e) Cusip Number: 438083107 Item 3: The person filing this Schedule 13G is an: X Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940 Item 4: Reference is made to Items 5-11 on the preceding pages of this Schedule 13G. Item 5: Ownership of Five Percent or Less of a Class This statement is being filed to report the fact that, as of the date of this report, the reporting person(s) has (have) ceased to be the beneficial owner of more than five percent of the class of securities. Item 6: Ownership of More than Five Percent on Behalf of Another Person (1) Price Associates does not serve as custodian of the assets of any of its clients; accordingly, in each instance only the client or the client's custodian or trustee bank has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. The ultimate power to direct the receipt of dividends paid with respect to, and the proceeds from the sale of, such securities, is vested in the individual and institutional clients which Price Associates serves as investment adviser. Any and all discretionary authority which has been delegated to Price Associates may be revoked in whole or in part at any time. Except as may be indicated if this is a joint filing with one of the registered investment companies sponsored by Price Associates which it also serves as investment adviser ("T. Rowe Price Funds"), not more than 5% of the class of such securities is owned by any one client subject to the investment advice of Price Associates. (2) With respect to securities owned by any one of the T. Rowe Price Funds, only the custodian for each of such Funds, has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. No other person is known to have such right, except that the shareholders of each such Fund participate proportionately in any dividends and distributions so paid. Item 7: Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not Applicable Item 8: Identification and Classification of Members of the Group Not Applicable Item 9: Notice of Dissolution of Group Not Applicable Item 10: Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. T. ROWE PRICE ASSOCIATES, INC. Date: February 16, 2021 Signature: /s/ David Oestreicher Name & Title: David Oestreicher, Executive Vice President 12/31/2020
    Get the next $FIXX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FIXX

    DatePrice TargetRatingAnalyst
    7/28/2023$9.00 → $1.50Outperform → Neutral
    Robert W. Baird
    2/28/2022$30.00 → $20.00Buy
    HC Wainwright & Co.
    2/22/2022$25.00 → $9.00Buy
    B of A Securities
    2/22/2022$35.00 → $29.00Neutral
    BTIG Research
    2/22/2022Outperform → Sector Perform
    RBC Capital Mkts
    2/22/2022$25.00 → $15.00Buy
    Chardan Capital
    2/22/2022$35.00 → $29.00Buy
    BTIG
    2/22/2022$30.00 → $4.00Outperform → Sector Perform
    RBC Capital
    More analyst ratings

    $FIXX
    Financials

    Live finance-specific insights

    See more
    • Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines' established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the U.S. with Homology Medicines as 20% owner

      Oxford Biomedica and Homology Medicines to establish Oxford Biomedica Solutions LLC, a new U.S.-based AAV Manufacturing and Innovation Business  Homology Medicines to receive $130 million from Oxford Biomedica to continue to advance its three clinical programs and genetic medicines platform Oxford Biomedica to invest $50 million to fund the growth of Oxford Biomedica Solutions LLC and will own 80%, with Homology Medicines to own 20%; Homology Medicines to secure preferred key customer status Dr. Roch Doliveux to become Interim CEO of Oxford Biomedica and John Dawson to retire as CEO and remain a Board Director of Oxford Biomedica Oxford Biomedica and Homology Medicines to host webcasts t

      1/28/22 2:30:00 AM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FIXX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Alloway Paul sold $6,488 worth of shares (268 units at $24.21), decreasing direct ownership by 9% to 2,596 units (SEC Form 4)

      4 - Q32 Bio Inc. (0001661998) (Issuer)

      4/23/24 5:03:07 PM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Michaud Charles Jr sold $1,815 worth of shares (75 units at $24.20), decreasing direct ownership by 7% to 927 units (SEC Form 4)

      4 - Q32 Bio Inc. (0001661998) (Issuer)

      4/23/24 5:00:03 PM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Tzianabos Arthur

      4 - Q32 Bio Inc. (0001661998) (Issuer)

      3/27/24 5:43:06 PM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FIXX
    SEC Filings

    See more
    • SEC Form 424B3 filed by Homology Medicines Inc.

      424B3 - Q32 Bio Inc. (0001661998) (Filer)

      5/9/24 7:26:07 AM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Homology Medicines Inc.

      10-Q - Q32 Bio Inc. (0001661998) (Filer)

      5/9/24 7:18:33 AM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Homology Medicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Q32 Bio Inc. (0001661998) (Filer)

      5/9/24 7:06:23 AM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FIXX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Homology Medicines downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded Homology Medicines from Outperform to Neutral and set a new price target of $1.50 from $9.00 previously

      7/28/23 7:17:02 AM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Homology Medicines with a new price target

      HC Wainwright & Co. reiterated coverage of Homology Medicines with a rating of Buy and set a new price target of $20.00 from $30.00 previously

      2/28/22 7:12:58 AM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • B of A Securities reiterated coverage on Homology Medicines with a new price target

      B of A Securities reiterated coverage of Homology Medicines with a rating of Buy and set a new price target of $9.00 from $25.00 previously

      2/22/22 10:12:45 AM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FIXX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Homology Medicines to Participate in the 43rd Annual Cowen Healthcare Conference

      BEDFORD, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a genetic medicines company, announced today that Albert Seymour, Ph.D., President and Chief Executive Officer, will participate in the "Gene Editing Corporate Panel" during the 43rd Annual Cowen Healthcare Conference on Wednesday, March 8, 2023 at 10:30 a.m. ET. The live webcast presentation will be accessible on Homology's website in the Investors section, and the webcast replay will be available on the website for 90 days following the presentation. About Homology Medicines, Inc.Homology Medicines, Inc. is a clinical-stage genetic medicines company dedicated to transforming the lives of patients

      3/2/23 7:30:54 AM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Homology Medicines to Participate at Upcoming Conferences

      BEDFORD, Mass., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a clinical-stage genetic medicines company, announced today participation at the following conferences. Cell & Gene Meeting on the Mesa Corporate presentation given by Albert Seymour, Ph.D., President and Chief Executive Officer of Homology, on October 11 at 3:15 p.m. PT"Gene Editing Accelerates: The First Generation Nears Approval While New Approaches Progress Through the Clinic" panel featuring Dr. Seymour on October 11 at 4:00 p.m. PT"New Business Models for Manufacturing Investment" panel featuring Arthur Tzianabos, Ph.D., Chairman of the Board of Homology, on October 12 at 3:15 p.m. PT

      10/6/22 8:30:27 AM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arthur Tzianabos, Ph.D., June Lee, MD FACCP, and Joseph Loscalzo, MD, Ph.D. Join 5AM Ventures

      SAN FRANCISCO and BOSTON, Sept. 27, 2022 (GLOBE NEWSWIRE) -- 5AM Ventures, a bicoastal venture capital firm, continues to attract preeminent talent as it celebrates 20 years of investing in early-stage life science companies. The firm is currently deploying capital in breakthrough science opportunities throughout North America and Europe from its $450 million 5AM Ventures VII fund and its $300 million 5AM Opportunities II fund, which has an additional mandate to invest in public market opportunities. 5AM is pleased to announce the addition of two Venture Partners to the firm's investment team, and a Venture Advisor to the advisory team. Dr. Arthur Tzianabos has joined 5AM as a Venture Pa

      9/27/22 8:15:00 AM ET
      $AKUS
      $CINC
      $FIXX
      $IONS
      Specialty Chemicals
      Consumer Discretionary
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FIXX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $FIXX
    Leadership Updates

    Live Leadership Updates

    See more
    • SEC Form SC 13G/A filed by Homology Medicines Inc. (Amendment)

      SC 13G/A - Q32 Bio Inc. (0001661998) (Subject)

      5/13/24 5:34:55 PM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Homology Medicines Inc.

      SC 13D - Q32 Bio Inc. (0001661998) (Subject)

      4/4/24 8:33:33 PM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Homology Medicines Inc.

      SC 13D - Q32 Bio Inc. (0001661998) (Subject)

      4/1/24 9:52:41 PM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Homology Medicines Appoints Gene Therapy Pioneer Beverly Davidson, Ph.D., as Chair of Scientific Advisory Board

      - ASGCT President and Entrepreneur Takes Leadership Role on SAB as Company Expects to Have Three Clinical Programs in 2021 - BEDFORD, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a clinical-stage genetic medicines company, announced today the appointment of gene therapy expert Beverly Davidson, Ph.D., as Chair of the Company's Scientific Advisory Board, on which she has served since 2018. Dr. Davidson is the Director of the Raymond G. Perelman Center for Cellular and Molecular Therapeutics, the Chief Scientific Strategy Officer, and holds the Arthur V. Meigs Chair in Pediatrics at the Children's Hospital of Philadelphia. She was also recently named Pr

      8/5/21 8:30:00 AM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care